Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs

Cardiovascular or arteriothrombotic adverse events (CV- or AT-AEs) are reported in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs). The incidence and characteristics across different TKI have not been systematically analyzed. We analyzed 531 patients treated wi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Jain, Preetesh, Kantarjian, Hagop, Boddu, Prajwal C., Nogueras-González, Graciela M., Verstovsek, Srdan, Garcia-Manero, Guillermo, Borthakur, Gautam, Sasaki, Koji, Kadia, Tapan M., Sam, Princy, Ahaneku, Hycienth, O’Brien, Susan, Estrov, Zeev, Ravandi, Farhad, Jabbour, Elias, Cortes, Jorge E.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Myeloid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6436011/
https://ncbi.nlm.nih.gov/pubmed/30885996
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018025874
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados